Tumor metabolic crosstalk and immunotherapy

Area of Science:

• Oncology
• Immunology
• Metabolic Research

Background:

• Tumor cells possess inherent robustness, resisting host immunity and thriving in acidic, hypoxic conditions.
• Solid tumors present challenges for immunotherapeutic agents due to tissue density and poor drug penetration.
• The tumor microenvironment (TME) significantly influences treatment efficacy and resistance.

Purpose of the Study:

• To explore the role of immunometabolic disorders in tumor progression and treatment resistance.
• To review metabolic factors influencing the TME and immunosuppression.
• To identify potential therapeutic targets within the tumor microenvironment for enhanced cancer immunotherapy.

Main Methods:

• Literature review summarizing substance metabolism in tumor progression.
• Analysis of the interplay between the TME and immunosuppression.
• Identification and discussion of potential tumor-site therapeutic targets.

Main Results:

• Immunometabolic disorders are identified as a key factor in treatment resistance at both the TME and host levels.
• The review highlights critical metabolic pathways and their impact on tumor growth and immune evasion.
• Specific TME-related factors and their potential as therapeutic targets are discussed.

Conclusions:

• Understanding tumor cell metabolism and its interaction with the immune system is crucial for effective cancer treatment.
• Targeting immunometabolic pathways within the TME presents a promising avenue for overcoming immunotherapy resistance.
• Further research into TME-targeted therapies is warranted to improve patient outcomes in cancer immunotherapy.